BRITISH COLUMBIA, Canada, Oct. 28 /CNW/ -- InNexus Biotechnology Inc.,
(OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug
development company commercializing the next generation of monoclonal
antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces
that Jeff Morhet, CEO and Chairman, will present at the 7th Annual BIO
Investor Forum on October 30, 2008.